|
|
Vaccine Detail
|
BCG HSP65-MUC1 Fusion Protein Vaccine |
| Vaccine Information |
- Vaccine Name: BCG HSP65-MUC1 Fusion Protein Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant protein vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Li et al., 2006)
- Immunization Route: subcutaneous injection
- Description: A recombinant fusion protein vaccine consisting of BCG-derived heat shock protein 65 (HSP65) fused to two copies of the MUC1 variable-number tandem repeat (VNTR) peptide, with potential antineoplastic activity. The HSP65 component acts as a self-adjuvant, activating dendritic cells via TLR2/4 signaling and facilitating MHC class I cross-presentation of MUC1 epitopes to generate tumor-specific CTL responses. In MUC1-expressing B16 melanoma models, prophylactic vaccination reduced tumor weight (0.11g vs 2.01g control, p<0.001) and increased survival (53-73% vs 7%). Therapeutic vaccination in MUC1-expressing B16 melanoma reduced tumor weight (1.23-1.71g vs 5.31g, p<0.05) and increased survival (50-75% vs 0%, p<0.001). Similar results were obtained in MUC1-expressing EL4 lymphoma models. HSP65-MUC1 induced MUC1-specific CD8+IFN-γ+ T cells (0.56% vs 0.02%) in immunized mice and activated human DC with upregulation of CD40, CD80, CD83, CD86, and HLA-A2. MUC1 is a membrane-bound glycoprotein overexpressed in various epithelial cancers including breast, ovarian, lung, and colon carcinomas (Li et al., 2006).
|
| Host Response |
|
|
| References |
Li et al., 2006: Li D, Li H, Zhang P, Wu X, Wei H, Wang L, Wan M, Deng P, Zhang Y, Wang J, Liu Y, Yu Y, Wang L. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity. European journal of immunology. 2006; 36(5); 1324-1336. [PubMed: 16619287].
|
|
